BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caines A, Selim R, Salgia R. The Changing Global Epidemiology of Hepatocellular Carcinoma. Clinics in Liver Disease 2020;24:535-47. [DOI: 10.1016/j.cld.2020.06.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Debes JD, Romagnoli PA, Prieto J, Arrese M, Mattos AZ, Boonstra A, On Behalf Of The Escalon Consortium. Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1681. [PMID: 33918270 DOI: 10.3390/cancers13071681] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Feng QS. Traditional Chinese medicine treatment of liver cirrhosis: Current status and future prospects. Shijie Huaren Xiaohua Zazhi 2021; 29(4): 159-164 [DOI: 10.11569/wcjd.v29.i4.159] [Reference Citation Analysis]
3 Boppana V, Sahni S, Glass J, Chang C, McCarthy DM. HCC You Cannot See. Dig Dis Sci 2021;66:2185-9. [PMID: 34089136 DOI: 10.1007/s10620-021-07070-7] [Reference Citation Analysis]
4 Zhu W, Ru L, Ma Z. Identification of a Novel Four-Gene Signature Correlated With the Prognosis of Patients With Hepatocellular Carcinoma: A Comprehensive Analysis. Front Oncol 2021;11:626654. [PMID: 33777771 DOI: 10.3389/fonc.2021.626654] [Reference Citation Analysis]
5 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma: Does the Background Liver With or Without Cirrhosis Matter? Am J Clin Pathol 2022;157:305-13. [PMID: 34542582 DOI: 10.1093/ajcp/aqab125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
8 Zhang C, Yang H, Pan L, Zhao G, Zhang R, Zhang T, Xiao Z, Tong Y, Zhang Y, Hu R, Pandol SJ, Han YP. Hepatitis B Virus X Protein (HBx) Suppresses Transcription Factor EB (TFEB) Resulting in Stabilization of Integrin Beta 1 (ITGB1) in Hepatocellular Carcinoma Cells. Cancers (Basel) 2021;13:1181. [PMID: 33803301 DOI: 10.3390/cancers13051181] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sun F, Liu Z, Wang B. Correlation between low-level viremia and hepatitis B-related hepatocellular carcinoma and recurrence: a retrospective study. BMC Cancer 2021;21:1103. [PMID: 34649509 DOI: 10.1186/s12885-021-08483-3] [Reference Citation Analysis]
10 Malagraba G, Yarmohammadi M, Javed A, Barceló C, Rubio-tomás T. The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update. Biomolecules 2022;12:462. [DOI: 10.3390/biom12030462] [Reference Citation Analysis]
11 Huang YH, Lian WS, Wang FS, Wang PW, Lin HY, Tsai MC, Yang YL. MiR-29a Curbs Hepatocellular Carcinoma Incidence via Targeting of HIF-1α and ANGPT2. Int J Mol Sci 2022;23:1636. [PMID: 35163556 DOI: 10.3390/ijms23031636] [Reference Citation Analysis]
12 Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. World J Gastroenterol 2021; 27(26): 3971-3983 [PMID: 34326608 DOI: 10.3748/wjg.v27.i26.3971] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Tohme S, Yazdani HO, Rahman A, Handu S, Khan S, Wilson T, Geller DA, Simmons RL, Molinari M, Kaltenmeier C. The Use of Machine Learning to Create a Risk Score to Predict Survival in Patients with Hepatocellular Carcinoma: A TCGA Cohort Analysis. Can J Gastroenterol Hepatol 2021;2021:5212953. [PMID: 34888264 DOI: 10.1155/2021/5212953] [Reference Citation Analysis]
14 Du L, Wang M, Li H, Li N, Wang F, Mei J. Identification of CCL20 and LCN2 as Efficient Serological Tools for Detection of Hepatocellular Carcinoma. Disease Markers 2022;2022:1-7. [DOI: 10.1155/2022/7758735] [Reference Citation Analysis]
15 Lupsor-Platon M, Serban T, Silion AI, Tirpe GR, Tirpe A, Florea M. Performance of Ultrasound Techniques and the Potential of Artificial Intelligence in the Evaluation of Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease. Cancers (Basel) 2021;13:790. [PMID: 33672827 DOI: 10.3390/cancers13040790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
16 Arif D, Mettler T, Adeyi OA. Mimics of hepatocellular carcinoma: a review and an approach to avoiding histopathological diagnostic missteps. Hum Pathol 2021;112:116-27. [PMID: 33346018 DOI: 10.1016/j.humpath.2020.12.002] [Reference Citation Analysis]
17 Li K, Liu J, Qin X. Research progress of gut microbiota in hepatocellular carcinoma. J Clin Lab Anal 2022;:e24512. [PMID: 35719048 DOI: 10.1002/jcla.24512] [Reference Citation Analysis]
18 Huang C, Fang M, Xiao X, Wang H, Gao Z, Ji J, Liu L, Gu E, Li Y, Wang M, Gao C. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study. Liver Int 2021. [PMID: 34679250 DOI: 10.1111/liv.15082] [Reference Citation Analysis]
19 Giannini EG. Improving prognosis of patients with very early hepatocellular carcinoma: How far are we going? Dig Liver Dis 2021;53:143-5. [PMID: 33257141 DOI: 10.1016/j.dld.2020.11.006] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Zou L, Sun P, Zhang L. miR-651-3p Enhances the Sensitivity of Hepatocellular Carcinoma to Cisplatin via Targeting ATG3-Mediated Cell Autophagy. J Oncol 2021;2021:5391977. [PMID: 34457004 DOI: 10.1155/2021/5391977] [Reference Citation Analysis]